Fundraising FoxCortex Pharmaceuticals Inc/De
Glen Rock, US · Delaware corporation
Find your way into Cortex Pharmaceuticals Inc/De
188 people in our graph can introduce you to the Cortex Pharmaceuticals Inc/De team.
Sign up to see every warm intro you have to Cortex Pharmaceuticals Inc/De
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cortex Pharmaceuticals Inc/De team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JE
Jeff E. MargolisExecutiveExecutive officer and director at RespireRx Pharmaceuticals, a biopharmaceutical company developing neuromodulator and cannabinoid-based drug candidates for neurological conditions including spinal cord injury, ADHD, epilepsy, and sleep-related disorders.
JS
James S.J. ManusoExecutive
RP
Richard PurcellSenior Vice President of Research and Development
RN
Robert N. WeingartenChief Financial Officer and Member of the Board of Directors
AS
Arnold S. LippaNamed on SEC filing
Board
KM
Kathryn MacFarlaneMember of the Board of Directors
JS
James SapirsteinMember of the Board of Directors
Reported raises · per SEC filings
Form D private placements$2.6M disclosed across 9 of 10 rounds · 2014–2020
▶$2MofferedAug 2020 · 1 investors · BiotechnologyRule 506(b)
▶$2MofferedAug 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold S. LippaExecutive Officer, Director
- Jeff E. MargolisExecutive Officer, Director
- Kathryn MacFarlaneDirector
- Richard PurcellExecutive Officer
- Timothy JonesExecutive Officer, Director
- Offering amount
- $2M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$193.3KraisedAug 2020 · 2 investors · BiotechnologyRule 506(b)
▶$193.3KraisedAug 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard PurcellExecutive Officer
- Arnold S. LippaExecutive Officer, Director
- Kathryn MacFarlaneDirector
- Jeff E. MargolisExecutive Officer, Director
- Timothy JonesExecutive Officer, Director
- Offering amount
- $193.3K
- Amount sold
- $193.3K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250.8KraisedSep 2018 · 10 investors · BiotechnologyRule 506(b)
▶$250.8KraisedSep 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeff E. MargolisExecutive Officer, Director
- James S. ManusoExecutive Officer, Director
- Arnold S. LippaExecutive Officer, Director
- James SapirsteinDirector
- Kathryn MacFarlaneDirector
- Richard PurcellExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $250.8K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75KraisedSep 2017 · 1 investors · BiotechnologyRule 506(b)
▶$75KraisedSep 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold S. LippaExecutive Officer, Director
- James S. ManusoExecutive Officer, Director
- Jeff E. MargolisExecutive Officer, Director
- Kathryn MacFarlaneDirector
- Richard PurcellExecutive Officer
- James SapirsteinDirector
- Offering amount
- $1.1M
- Amount sold
- $75K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50KraisedMar 2017 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedMar 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold S. LippaExecutive Officer, Director
- Richard PurcellExecutive Officer
- James S. ManusoExecutive Officer, Director
- James SapirsteinDirector
- Kathryn MacFarlaneDirector
- Jeff E. MargolisExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $50K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$185KraisedJan 2017 · 4 investors · BiotechnologyRule 506(b)
▶$185KraisedJan 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James SapirsteinDirector
- Jeff E. MargolisExecutive Officer, Director
- Arnold S. LippaExecutive Officer, Director
- Richard PurcellExecutive Officer
- James S. ManusoExecutive Officer, Director
- Kathryn MacFarlaneDirector
- Robert N. WeingartenExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $185K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedJan 2016 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedJan 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert N. WeingartenExecutive Officer, Director
- James SapirsteinDirector
- Jeff E. MargolisExecutive Officer, Director
- Arnold S. LippaExecutive Officer, Director
- Kathryn MacFarlaneDirector
- Richard PurcellExecutive Officer
- James S.J. ManusoExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $100K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$721.2KraisedSep 2015 · 8 investors · BiotechnologyRule 506(b)
▶$721.2KraisedSep 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathryn MacFarlaneDirector
- Jeff E. MargolisExecutive Officer, Director
- James S.J. ManusoExecutive Officer, Director
- Arnold S. LippaExecutive Officer, Director
- James SapirsteinDirector
- Richard PurcellExecutive Officer
- Robert N. WeingartenExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $721.2K
- Sales commissions
- $47.1K
- Proceeds to insiders
- $40K
- Placement agents
- Aurora Capital LLC, Gelband & Co., Inc.
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Cortex Pharmaceuticals Inc/De raised?
- Cortex Pharmaceuticals Inc/De has disclosed $2.6M raised across 9 of its 10 known rounds.
- Where is Cortex Pharmaceuticals Inc/De headquartered?
- Cortex Pharmaceuticals Inc/De is headquartered in Glen Rock, US.